Lupin gets USFDA nod to market a generic drug to treat bacterial infections
Drug maker Lupin said it has received approval from the US health regulator to market a generic medication to treat bacterial infections, in America.
The company has received approval from the USFDA for Doxycycline for Injection USP, the Mumbai-based drug maker said in a statement.
The company's product is the generic equivalent of Pfizer Inc's Vibramycin for injection, it added.
Also Read:Lupin names Rakesh Bhardwaj as Chief Information Officer
The product will be manufactured at its Nagpur facility, Lupin said.
Doxycycline for Injection USP is indicated to reduce the development of drug-resistant bacteria.
As per the IQVIA MAT January 2024 data, Doxycycline for Injection USP had estimated annual sales of USD 47 million in the US market.
Original news source: https://www.ptinews.com/story/business/lupin-gets-usfda-nod-for-generic-antibacterial-drug/1360777
